NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Receives Average Recommendation of “Hold” from Analysts

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has earned an average rating of “Hold” from the five brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $11.6667.

A number of research analysts have weighed in on NMTC shares. Weiss Ratings lowered shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. LADENBURG THALM/SH SH lifted their price target on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. JonesTrading started coverage on shares of NeuroOne Medical Technologies in a research note on Monday, March 2nd. They issued a “buy” rating and a $9.00 price target on the stock. Wall Street Zen raised shares of NeuroOne Medical Technologies to a “sell” rating in a research note on Saturday, February 21st. Finally, Zacks Research lowered shares of NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 13th.

Insiders Place Their Bets

In related news, insider David J. Wambeke purchased 166,666 shares of the business’s stock in a transaction on Sunday, March 1st. The shares were purchased at an average price of $4.02 per share, with a total value of $669,997.32. Following the completion of the purchase, the insider owned 166,666 shares in the company, valued at $669,997.32. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 2,438 shares of company stock valued at $11,702 over the last 90 days. Insiders own 11.80% of the company’s stock.

Institutional Trading of NeuroOne Medical Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in NMTC. Legato Capital Management LLC acquired a new stake in shares of NeuroOne Medical Technologies in the fourth quarter valued at approximately $34,000. Squarepoint Ops LLC acquired a new stake in shares of NeuroOne Medical Technologies in the fourth quarter valued at approximately $36,000. Susquehanna International Group LLP acquired a new stake in shares of NeuroOne Medical Technologies in the third quarter valued at approximately $47,000. XTX Topco Ltd acquired a new stake in shares of NeuroOne Medical Technologies in the second quarter valued at approximately $51,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of NeuroOne Medical Technologies in the first quarter valued at approximately $84,000. 16.07% of the stock is currently owned by institutional investors and hedge funds.

NeuroOne Medical Technologies Price Performance

NeuroOne Medical Technologies stock opened at $3.69 on Friday. The company’s 50 day simple moving average is $4.47 and its 200 day simple moving average is $4.53. NeuroOne Medical Technologies has a fifty-two week low of $3.27 and a fifty-two week high of $6.96. The firm has a market capitalization of $31.81 million, a price-to-earnings ratio of -4.34 and a beta of 0.60.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 98.33%. The company had revenue of $2.39 million during the quarter, compared to the consensus estimate of $2.58 million. As a group, analysts predict that NeuroOne Medical Technologies will post -0.35 EPS for the current fiscal year.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.